The EU Commission fines pharmaceutical companies for pay-for-delay agreement (Teva / Cephalon)

On 26 November 2020, the European Commission ("Commission") announced that it had fined the pharmaceutical companies Teva and Cephalon EUR 60.5 million for agreeing to delay for several years the market entry of a cheaper generic version of Cephalon's drug for sleep disorders, modafinil, after Cephalon's main patents had expired, in breach of Article 101 TFEU (the prohibition of anticompetitive agreements). WHAT YOU NEED TO KNOW - KEY TAKEAWAYS The decision completes the cycle of pay-for-delay pharmaceutical investigations launched with

L'accès à cet article est réservé aux abonnés

Déjà abonné ? Identifiez-vous

L’accès à cet article est réservé aux abonnés.

Lire gratuitement un article

Vous pouvez lire cet article gratuitement en vous inscrivant.

 

Version PDF

Auteurs

  • Ashurst (London)
  • Ashurst (London)

Citation

Duncan Liddell, Steven Vaz, The EU Commission fines pharmaceutical companies for pay-for-delay agreement (Teva / Cephalon), 26 novembre 2020, e-Competitions November 2020, Art. N° 98232

Visites 115

Tous les numéros

  • Latest News issue 
  • Tous les News issues
  • Latest Special issue 
  • Tous les Special issues